Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety contract research organization (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in providing small molecules and early discovery services of drugs, announced that Metrion has enhanced its high-throughput screening (HTS) services by adding access to Enamine compound libraries.
The Enamine compound library collection is the largest in the world and includes libraries of both CNS and ion channel-focused targets. Libraries can be partitioned into distinct screening sets, allowing increased flexibility and efficiency in screening and target identification. In addition, “analog by catalog” from stock Enamine libraries and “make-on-demand REAL libraries” present a fast and cost-effective solution for hit extension and SAR (structure-activity relationship) studies.
To ensure diversity and cost-effectiveness, researchers can access expert advice from Metrion’s team of ion channel and HTS experts to determine the most effective approach. The Company will also provide a structured data archive of all libraries for comparison with existing libraries, further increasing efficiency.
Metrion’s HTS capabilities were launched in November 2022 as an addition to its extensive preclinical ion channel drug discovery and pharmacology services to complement the Company’s automated and conventional electrophysiology services. Metrion’s HTS capabilities include 384-well testing via FLIPR Penta and Qube-384 systems. The services provide significant additional capacity and flexibility to support ion channel drug discovery projects for the Company’s global customer base.
Combining our specialized ion channel expertise with substantial HTS and hit discovery experience gives clients access to a dedicated team of drug discovery scientists, ensuring the right strategic choices are made in compounds selected for testing. This additional access to the highest quality control libraries from Enamine increases diversity and allows Metrion to maximize R&D budgets even more efficiently.
Gary Clark, Director of Screening Technologies, Metrion Biosciences
Enamine is focused on providing new chemical compounds to support drug discovery. We are delighted that Metrion is adding access to our libraries to the HTS services it offers. Enamine is also able to support the next steps of the discovery process, including hit sourcing, rationing from our REAL in-stock libraries and ordering, and custom compounding of advanced hits and leads.
Vladimir Ivanov, Executive Vice President, Enamine
